No quarterly revenue total was found in Advanced Biomed Inc.'s SEC filings.
Advanced Biomed Inc. (ADVB) files with the SEC under industry code 8071, Services-Medical Laboratories.
Revenue
—
Net income
$694,999
+199.1% vs year-ago quarter
Operating cash flow
$-583,268
+62.2% vs year-ago quarter
Free cash flow
$-241,039
+92.9% vs year-ago quarter
EPS
$0.44
+168.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
1.65M
-92.4% vs year-ago quarter
Net cash
$2.57M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- ADVB (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- NV
- Headquarters
- Reno, NV
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1941029
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q4 FY2026 Jun 30, 2026 |
Q3 FY2026 Mar 31, 2026 |
Q2 FY2026 Dec 31, 2025 |
Q1 FY2026 Sep 30, 2025 |
Q4 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Net income | $694,999 | -$488,942 | $6.9M | -$386,901 | -$701,611 |
| Diluted EPS | $0.44 | -$0.38 | $0.31 | -$0.02 | -$0.65 |
| Operating cash flow | -$583,268 | -$239,775 | -$513,558 | -$610,342 | -$1.5M |
| Free cash flow | — | -$241,039 | -$526,464 | -$612,113 | -$1.6M |
| Total assets | $13.8M | $10.6M | $10.9M | $6.2M | $22.9M |
| Total liabilities | $1.5M | $1.4M | $1.4M | $3.2M | $19.4M |
| Stockholders' equity | $12.3M | $9.2M | $9.5M | $3.0M | $3.5M |
| Cash and investments | $385,535 | $2.6M | $2.6M | $2.7M | $31,139 |
| Total debt | — | $29,511 | $21,092 | $30,869 | $41,690 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-K | Annual report | Oct 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Agreement ended
|
Jul 17, 2026 | Jul 14, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jul 1, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement
|
Jun 30, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Acquisition or sale of assets, Unregistered share sale, Officer or director change
|
May 1, 2026 | Apr 28, 2026 |
All 98 Advanced Biomed Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.